2012-08-07T14:29:34-05:00 2011-09-30 CLIFTONLARSONALLEN LLP 2900 SOUTH QUINCY ST SUITE 150 ARLINGTON VA 22206 990 2010-10-01 850422250 UNITED STATES INDUSTRY COALITION UNIT 7035269447 1600 WILSON BOULEVARD NO 1010 ARLINGTON VA 22209 JOHN W PEEL III 7035269447 2012-08-06 1 JENNIFER M ALDRIDGE 7039985100 2010 2016-02-24 21:20:13Z JOHN W PEEL III 1600 WILSON BOULEVARD NO 1010 ARLINGTON VA 22209 1626914 0 X WWW.USIC.NET X 1994 DE ADVANCING NON PROLIFERATION AND OTHER HUMANITARIAN GOALS THROUGH TECHNOLOGY COMMERCIALIZATION 10 10 14 12 0 0 45000 0 1676820 1624899 3854 2015 0 0 1725674 1626914 0 0 0 0 1005496 893938 0 0 0 804350 721061 1809846 1614999 -84172 11915 844390 794453 203166 141314 641224 653139 X USIC IS A NON-PROFIT ORGANIZATION FACILITATING COMMERCIAL PARTNERSHIPS BETWEEN U.S. BUSINESS AND SCIENTIFIC AND ENGINEERING ENTITIES IN THE FORMER SOVIET UNION FOR THE PURPOSE OF ADVANCING NONPROLIFERATION OF WEAPONS OF MASS DESTRUCTION. 1 0 1462179 1462179 SUPPORT FOR GOVERNMENT'S INITIATIVE FOR PROLIFERATION PREVENTION PROGRAMS - USIC CONTINUES TO SUPPORT TECHNOLOGY COMMERCIALIZATION PROJECTS, WHICH REDUCE THE PROLIFERATION THREAT AND ASSIST NIS INSTITUTES IN BRINGING TECHNOLOGY THEY DEVELOPED TO MARKET. THE PROCESS HAS NOT CHANGED SINCE USIC'S INCEPTION WITH A MEMBER ENTERING INTO A COST SHARING ARRANGEMENT WITH A NATIONAL LABORATORY WHO IN TURN CONTRACTS WITH A NIS INSTITUTE TO PERFORM THE WORK. 12000 OUR LAW FIRM, PILLSBURY WINTHROP SHAW PITTMAN, PROVIDED US WITH A PRO BONO JUNIOR ATTORNEY FOR NINE MONTHS UNDER ITS FIRST-YEAR DEFERRED JUNIOR ASSOCIATE PROGRAM. TYPICALLY, PWSP AND OTHER LAW FIRMS USE THIS KIND OF PROGRAM TO PLACE FIRST-YEAR ASSOCIATES IN PUBLIC DEFENDERS' OFFICES. IN THIS CASE, THE ATTORNEY, MR. KHURRAM CHIPPA, HAD SPECIAL INTEREST IN USING THE OPPORTUNITY TO GAIN EXPERIENCE IN NONPROFITS AND MARKETING, SO PWSP ADAPTED THE PROGRAM SO HE COULD WORK PRO BONO FOR US. UNDER THE TERMS OF THE AGREEMENT WITH PWSP, PWSP MADE A DONATION OF $45,000 TO USIC TO COVER SALARY AND ALL OTHER COSTS OF MR. CHIPPA'S TENURE WITH US, INCLUDING SALARY AND ANY BENEFITS WE MUTUALLY AGREED ON WITH HIM. 27205 75000 ON JULY 15, 2011, USIC ENTERED INTO AN AGREEMENT TO INTRODUCE OXYPLASMA (A SYNTHETIC BLOOD SUBSTITUTE) TO THE DOD FOR SURGICAL USE AND BATTLEFIELD TRAUMA MANAGEMENT. DEVELOPED BY THE MENSA CORPORATION, THE PRODUCT IS BEING PRESENTED TO THE FDA FOR ACCEPTANCE INTO PHASE II TRIALS. USIC'S ROLE INCLUDES WORKING WITH THE PRODUCT DEVELOPER, THE DOD, AND THE THIRD PARTY ADVISOR TO TRANSLATE END USER REQUIREMENTS INTO AN ACCEPTABLE TESTING CONFIGURATION. OXYPLASMA REDUCES THE DEPENDENCY FOR HUMAN BLOOD RESERVES WHICH COULD BE TAINTED WITH DISEASE (HIV AND HEPATITIS). ITS APPLICATION IS DESIGNED FOR SIGNIFICANT BLOOD LOSS SITUATIONS. SYNTHETIC BLOOD ADVANTAGES ALSO INCLUDE EASE OF TRANSPORT AND STORAGE (LONG SHELF-LIFE). USIC ANTICIPATES THAT THESE ADVANTAGES WILL REDUCE THE BURDEN ON GOVERNMENT. 32859 32859 ESCROW FUNDS 32859 32859 1534243 1 0 0 1 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 20 0 14 1 0 0 0 0 0 0 0 0 0 0 X 10 10 0 0 0 0 1 1 0 1 0 0 0 0 1 1 1 1 1 1 1 0 X THE ORGANIZATION YEOJEUNG SUH 7035269447 1600 WILSON BLVD SUITE 1010 ARLINGTON VA 22209 DR JAMES E THOMPSON 1.00 X X 0 0 0 DR LARRY G STOLARCZYK 1.00 X X 0 0 0 CHARLES H PETERSON 1.00 X 0 0 0 DAVID C BELL 1.00 X 0 0 0 CORNELIUS J MILMOE 1.00 X 0 0 0 JOHN J GALLAGHER 1.00 X 0 0 0 DR STANLEY SATZ 1.00 X 0 0 0 JULIANA C SHEI 1.00 X 0 0 0 RICHARD F TESTA 1.00 X 0 0 0 DR MICHAEL WALDMAN 1.00 X 0 0 0 KENNETH PEDDICORD 1.00 X 0 0 0 DR NORMAN P NEUREITER 1.00 X 0 0 0 DR GERSON S SHER 40.00 X 144167 0 2579 DR JOHN W PEEL 40.00 X 120642 0 51260 264809 0 53839 2 0 1 0 0 U.S. GOVERNMENT GRANTS 900099 1462179 1462179 CONTRACTS 900099 75000 75000 MEMBERSHIP DUES 900099 50028 50028 MEETING REVENUE 900099 4833 4833 32859 32859 1624899 2015 2015 1626914 1624899 0 2015 300787 234208 66579 366603 350007 16596 10958 10958 163524 163524 52066 52066 49611 18755 30856 139315 139315 94000 34000 60000 71293 33377 37916 134305 134305 33936 29045 4891 13275 4034 9241 13251 13251 DIRECT PROGRAMS 147153 147153 LICENSE AND FEES 8192 8192 FRINGE BENEFIT ALLOCATI 0 252558 -252558 INDIRECT COST ALLOCATIO 0 431106 -431106 16730 16730 1614999 1534243 80756 0 130816 49777 634898 580298 80218 30436 56638 43708 22038 10016 844390 794453 74660 100611 60506 37560 68000 3143 203166 141314 X 629224 653139 12000 0 641224 653139 844390 794453 11915 0 X 0 1 1 X 1 1 X 1979551 1851020 1743937 1626706 1462179 8663393 1979551 1851020 1743937 1626706 1462179 8663393 8663393 21589 25992 10812 3854 2015 64262 8727655 761412 0.99260 0.99220 X 43030 43030 1571969 1614999 230750 57688 0 0 248996 251959 240492 230750 972197 1458296 58239 46500 94000 43030 241769 62249 62990 60123 57688 243050 364575 0 DEFERRED RENT 3143 3143 1626914 1614999 11915 0 11915 1626914 0 1626914 0 1626914 1614999 0 1614999 0 1614999 DESCRIPTION OF UNCERTAIN TAX POSITIONS UNDER FIN 48: PART X: IN JUNE 2006, THE FINANCIAL ACCOUNTING STANDARDS BOARD (FASB) RELEASED FASB ASC 740-10, INCOME TAXES, THAT PROVIDES GUIDANCE FOR REPORTING UNCERTAINTY IN INCOME TAXES. FOR THE YEAR ENDED SEPTEMBER 30, 2011, USIC HAS DOCUMENTED ITS CONSIDERATION OF FASB ASC 740-10 AND DETERMINED THAT NO MATERIAL UNCERTAIN TAX POSITIONS QUALIFY FOR EITHER RECOGNITION OR DISCLOSURE IN THE FINANCIAL STATEMENTS. THE FEDERAL FORM 990, RETURN OF ORGANIZATION EXEMPT FROM INCOME TAX, IS SUBJECT TO EXAMINATION BY THE INTERNAL REVENUE SERVICE, GENERALLY FOR THREE YEARS AFTER IT IS FILED. X 0 0 0 0 0 0 0 0 0 DR JOHN W PEEL 120642 0 0 0 0 0 3094 0 48166 0 171902 0 0 0 NEW PROGRAM SERVICES FORM 990, PART III, LINE 2 ON JULY 15, 2011, USIC ENTERED INTO AN AGREEMENT TO INTRODUCE OXYPLASMA (A SYNTHETIC BLOOD SUBSTITUTE) TO THE DOD FOR SURGICAL USE AND BATTLEFIELD TRAUMA MANAGEMENT. DEVELOPED BY THE MENSA CORPORATION, THE PRODUCT IS BEING PRESENTED TO THE FDA FOR ACCEPTANCE INTO PHASE II TRIALS. USIC'S ROLE INCLUDES WORKING WITH THE PRODUCT DEVELOPER, THE DOD, AND THE THIRD PARTY ADVISOR TO TRANSLATE END USER REQUIREMENTS INTO AN ACCEPTABLE TESTING CONFIGURATION. OXYPLASMA REDUCES THE DEPENDENCY FOR HUMAN BLOOD RESERVES WHICH COULD BE TAINTED WITH DISEASE (HIV AND HEPATITIS). ITS APPLICATION IS DESIGNED FOR SIGNIFICANT BLOOD LOSS SITUATIONS. SYNTHETIC BLOOD ADVANTAGES ALSO INCLUDE EASE OF TRANSPORT AND STORAGE (LONG SHELF-LIFE). USIC ANTICIPATES THAT THESE ADVANTAGES WILL REDUCE THE BURDEN ON GOVERNMENT. FORM 990, PART VI, SECTION A, LINE 1 THE BOARD DELEGATED OVERSIGHT OF THE ORGANIZATION'S ANNUAL AUDIT TO THE AUDIT COMMITTEE. THE AUDIT COMMITTEE IS MADE UP OF ONE MEMBER, WHO IS THE CHAIRMAN OF THE AUDIT COMMITTEE. THE MEMBER OF THE AUDIT COMMITTEE IS ALSO A BOARD MEMBER. THE AUDIT COMMITTEE HAS AUTHORITY TO OVERSEE THE AUDIT PROCESS FROM THE SELECTION OF THE INDEPENDENT AUDITOR TO THE FINAL AUDITED FINANCIAL STATEMENTS. FORM 990, PART VI, SECTION A, LINE 6 USIC'S MEMBERS ARE BUSINESSES WHICH ARE AFFILIATED WITH THE DOE PROGRAM CALLED GLOBAL INITIATIVES FOR PROLIFERATION PREVENTION (GIPP) AND THOSE WHO ARE NOT CALLED GENERAL MEMBERSHIP. THE GIPP CATEGORIES FOR U.S. BUSINESSES ARE LARGE BUSINESSES, SMALL BUSINESSES, ASSOCIATE MEMBERS AND UNIVERSITIES. THE GENERAL MEMBERSHIP CATEGORIES ARE THE SAME AS THE GIPP CATEGORIES EXCEPT THEY ARE FOR NON-GIPP BUSINESSES AND FOREIGN ENTITIES. FORM 990, PART VI, SECTION A, LINE 7A ONLY MEMBERS WHO PARTICIPATE IN THE GIPP PROGRAM, NOW CALLED "GIPP MEMBERS", MAY VOTE FOR DIRECTORS. GENERAL MEMBERS ARE ELIGIBLE FOR ALL OTHER USIC SERVICES BUT NOT TO VOTE IN ELECTIONS FOR USIC'S DIRECTORS. FORM 990, PART VI, SECTION A, LINE 8B THE AUDIT COMMITTEE REPORTS TO THE BOARD DURING THE REGULARLY SCHEDULED BOARD OF DIRECTOR MEETINGS. FORM 990, PART VI, SECTION B, LINE 11 THE FORM 990 IS PREPARED BY USIC'S EXTERNAL ACCOUNTANTS. A COPY IS PROVIDED TO THE EXECUTIVE VICE PRESIDENT FOR REVIEW, AND ANY CHANGES OR QUESTIONS ARE SENT BACK TO THE INDEPENDENT ACCOUNTANT. ONCE THE FINAL DRAFT COPY IS RECEIVED, IT IS FORWARDED TO THE CHAIRMAN OF THE AUDIT COMMITTEE FOR HIS REVIEW BEFORE IT IS FILED WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C ONCE A YEAR, THE BOARD MEMBERS AT THEIR MEETING MUST READ AND SIGN A CONFLICT OF INTEREST DISCLOSURE FORM. THE OFFICERS AND KEY EMPLOYEES SIGN A CONFLICT OF INTEREST DISCLOSURE FORM UPON HIRE. FORM 990, PART VI, SECTION B, LINE 15 SALARIES OF THE PRESIDENT AND EXECUTIVE VICE PRESIDENT ARE SET BY USIC'S BOARD OF DIRECTORS. THE PRESIDENT APPROVES THE SALARIES OF OTHER PAID OFFICERS AND KEY EMPLOYEES, WHICH ARE SET DURING THE RECRUITMENT PROCESS BASED ON COMPARABILITY DATA. FORM 990, PART VI, SECTION C, LINE 19 THE BYLAWS ARE POSTED ON USIC'S WEBSITE. THE CONFLICT OF INTEREST POLICY IS AVAILABLE UPON REQUEST. THE AUDITED FINANCIAL STATEMENTS ARE INCLUDED IN THE PRINTED ANNUAL REPORT, WHICH IS ALSO AVAILABLE ON USIC'S WEBSITE.